Viridian Therapeutics Shares Plunge After Phase 3 Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy VRDN?
Source: stocktwits
Viridian Therapeutics Inc. shares fell 32% after hitting a 20-day low, following the announcement of phase 3 trial results for elegrobart, which met its primary endpoint for treating thyroid eye disease.
Despite the positive trial results, investor expectations were not met, leading to a significant stock decline. The efficacy data showed a responder rate of 54% in the four-week dosing group, but overall market sentiment was dampened by an analyst's disappointment regarding the drug's efficacy profile. Viridian plans to submit a Biologics License Application for elegrobart in Q1 2027, but the market reaction indicates skepticism about its future performance.
The implications of this decline suggest that while the trial results were technically positive, the market's reaction reflects a deeper concern about the drug's potential in a competitive landscape. Investors may need to reassess their expectations as the company moves forward with its plans.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRDN
Wall Street analysts forecast VRDN stock price to rise
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.960
Low
14.20
Averages
41.71
High
61.00
Current: 13.960
Low
14.20
Averages
41.71
High
61.00
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surge in Options Trading Volume for OraSure and Viridian
- OraSure Options Volume: OraSure Technologies Inc. experienced options trading volume of 3,510 contracts, representing approximately 351,000 shares, which is about 62.6% of its average daily trading volume of 560,775 shares over the past month, indicating heightened market interest in its future performance.
- High Demand for Call Options: Notably, the $2.50 strike call option expiring on April 17, 2026, saw trading of 3,500 contracts today, representing around 350,000 shares, suggesting investor optimism regarding OraSure's prospects.
- Viridian Options Volume: Viridian Therapeutics Inc. recorded options trading volume of 14,194 contracts, equating to approximately 1.4 million shares, or about 61% of its average daily trading volume of 2.3 million shares over the past month, reflecting strong investor interest in the company.
- Active Trading of Put Options: Particularly, the $14 strike put option expiring on May 15, 2026, has seen trading of 5,002 contracts today, representing approximately 500,200 shares, indicating market concerns regarding potential risks facing Viridian in the future.
See More
Amgen's Phase 3 Trial Success Leads to Viridian Stock Plunge
- Amgen Trial Results: Amgen's Phase 3 trial achieved its primary goal, with 77% of patients showing significant improvement in eye bulging, indicating the effectiveness of its drug Tepezza for thyroid eye disease, which could positively impact market dynamics.
- Viridian Drug Performance: Viridian's Elegrobar reduced eye bulging by approximately 54% and 63% over four and eight weeks, respectively, although its efficacy is lower than Amgen's; however, its simpler subcutaneous injection method may provide a competitive edge in the market.
- Stock Price Volatility: Viridian's shares plummeted 23% on Monday, hitting the lowest point since June 3, 2025, reflecting market disappointment over its Phase 3 trial results, particularly due to limited inflammation improvement and reports of tinnitus.
- Market Sentiment Shift: Despite the stock's decline, retail sentiment on Stocktwits shifted from 'extremely bullish' to 'bullish', indicating some market participants expect a rebound, with predictions of the stock rising to $25 by the end of the week.
See More
Viridian Therapeutics Shares Plummet: The Connection to an Amgen Study Explained.
- Viridian Therapeutics Stock Reaction: Viridian Therapeutics' stock experienced a decline on Monday.
- Amgen's Phase 3 Trial Results: The drop followed Amgen's announcement of positive results from a Phase 3 trial for a new treatment targeting thyroid eye disease.
See More
Stock Movers: Seagate, Micron, Tesla, Kratos, Strategy, Soleno, Viridian, and Others
- Market Reaction: Stocks experienced an increase on Monday as investors remained optimistic about a potential peace agreement between the U.S. and Iran.
- Deadline Pressure: The optimism is linked to a looming Tuesday evening deadline concerning threatened strikes on power plants by the president.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Immunovant Reports Disappointing Trial Results, Shares Drop
- Clinical Trial Results: Immunovant's two late-stage trials failed to meet the primary endpoint, although patients showed significant improvement in eye bulging during the initial 12-week high-dose treatment, indicating the potential importance of IgG antibody suppression.
- Stock Reaction: Following the disappointing topline results, Immunovant (IMVT) shares fell 12% in pre-market trading, and if this level holds after the opening bell, it would mark the lowest point in nearly four months, reflecting market pessimism about its future prospects.
- Shift in Treatment Focus: Immunovant plans to shift its focus to the development of IMVT-1402, targeting multiple autoimmune diseases with Graves' disease as a priority, and early Phase 2 data suggest this therapy may help modify the disease, with topline results from late-stage studies expected in 2027.
- Intensifying Market Competition: In the same week that Immunovant reported its results, Viridian Therapeutics (VRDN) also announced its Phase 3 results for treating thyroid eye disease, which met its primary goal but showed limited improvements in inflammation, highlighting the competitive intensity in this therapeutic area.
See More
Surge in Options Trading Volume for OraSure and Viridian
- OraSure Options Volume: OraSure Technologies Inc. experienced options trading volume of 3,510 contracts, representing approximately 351,000 shares, which is about 62.6% of its average daily trading volume of 560,775 shares over the past month, indicating heightened market interest in its future performance.
- High Demand for Call Options: Notably, the $2.50 strike call option expiring on April 17, 2026, saw trading of 3,500 contracts today, representing around 350,000 shares, suggesting investor optimism regarding OraSure's prospects.
- Viridian Options Volume: Viridian Therapeutics Inc. recorded options trading volume of 14,194 contracts, equating to approximately 1.4 million shares, or about 61% of its average daily trading volume of 2.3 million shares over the past month, reflecting strong investor interest in the company.
- Active Trading of Put Options: Particularly, the $14 strike put option expiring on May 15, 2026, has seen trading of 5,002 contracts today, representing approximately 500,200 shares, indicating market concerns regarding potential risks facing Viridian in the future.
See More
Amgen's Phase 3 Trial Success Leads to Viridian Stock Plunge
- Amgen Trial Results: Amgen's Phase 3 trial achieved its primary goal, with 77% of patients showing significant improvement in eye bulging, indicating the effectiveness of its drug Tepezza for thyroid eye disease, which could positively impact market dynamics.
- Viridian Drug Performance: Viridian's Elegrobar reduced eye bulging by approximately 54% and 63% over four and eight weeks, respectively, although its efficacy is lower than Amgen's; however, its simpler subcutaneous injection method may provide a competitive edge in the market.
- Stock Price Volatility: Viridian's shares plummeted 23% on Monday, hitting the lowest point since June 3, 2025, reflecting market disappointment over its Phase 3 trial results, particularly due to limited inflammation improvement and reports of tinnitus.
- Market Sentiment Shift: Despite the stock's decline, retail sentiment on Stocktwits shifted from 'extremely bullish' to 'bullish', indicating some market participants expect a rebound, with predictions of the stock rising to $25 by the end of the week.
See More
Viridian Therapeutics Shares Plummet: The Connection to an Amgen Study Explained.
- Viridian Therapeutics Stock Reaction: Viridian Therapeutics' stock experienced a decline on Monday.
- Amgen's Phase 3 Trial Results: The drop followed Amgen's announcement of positive results from a Phase 3 trial for a new treatment targeting thyroid eye disease.
See More
Stock Movers: Seagate, Micron, Tesla, Kratos, Strategy, Soleno, Viridian, and Others
- Market Reaction: Stocks experienced an increase on Monday as investors remained optimistic about a potential peace agreement between the U.S. and Iran.
- Deadline Pressure: The optimism is linked to a looming Tuesday evening deadline concerning threatened strikes on power plants by the president.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Immunovant Reports Disappointing Trial Results, Shares Drop
- Clinical Trial Results: Immunovant's two late-stage trials failed to meet the primary endpoint, although patients showed significant improvement in eye bulging during the initial 12-week high-dose treatment, indicating the potential importance of IgG antibody suppression.
- Stock Reaction: Following the disappointing topline results, Immunovant (IMVT) shares fell 12% in pre-market trading, and if this level holds after the opening bell, it would mark the lowest point in nearly four months, reflecting market pessimism about its future prospects.
- Shift in Treatment Focus: Immunovant plans to shift its focus to the development of IMVT-1402, targeting multiple autoimmune diseases with Graves' disease as a priority, and early Phase 2 data suggest this therapy may help modify the disease, with topline results from late-stage studies expected in 2027.
- Intensifying Market Competition: In the same week that Immunovant reported its results, Viridian Therapeutics (VRDN) also announced its Phase 3 results for treating thyroid eye disease, which met its primary goal but showed limited improvements in inflammation, highlighting the competitive intensity in this therapeutic area.
See More
